Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
RIGL's Cash to Debt is ranked higher than
99% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. RIGL: No Debt )
RIGL' s 10-Year Cash to Debt Range
Min: 4.48   Max: No Debt
Current: No Debt

Interest Coverage No Debt
RIGL's Interest Coverage is ranked higher than
76% of the 454 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.71 vs. RIGL: No Debt )
RIGL' s 10-Year Interest Coverage Range
Min: 388.1   Max: 9999.99
Current: No Debt

388.1
9999.99
F-Score: 4
Z-Score: 0.85
M-Score: -0.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1251.31
RIGL's Operating margin (%) is ranked lower than
57% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. RIGL: -1251.31 )
RIGL' s 10-Year Operating margin (%) Range
Min: -14938.27   Max: 28.25
Current: -1251.31

-14938.27
28.25
Net-margin (%) -1245.13
RIGL's Net-margin (%) is ranked lower than
57% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. RIGL: -1245.13 )
RIGL' s 10-Year Net-margin (%) Range
Min: -14872.93   Max: 30.31
Current: -1245.13

-14872.93
30.31
ROE (%) -42.75
RIGL's ROE (%) is ranked lower than
53% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. RIGL: -42.75 )
RIGL' s 10-Year ROE (%) Range
Min: -1635.71   Max: 22.81
Current: -42.75

-1635.71
22.81
ROA (%) -39.38
RIGL's ROA (%) is ranked lower than
53% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. RIGL: -39.38 )
RIGL' s 10-Year ROA (%) Range
Min: -92   Max: 20.3
Current: -39.38

-92
20.3
ROC (Joel Greenblatt) (%) -2008.28
RIGL's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. RIGL: -2008.28 )
RIGL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4890.31   Max: 778.94
Current: -2008.28

-4890.31
778.94
Revenue Growth (%) -67.70
RIGL's Revenue Growth (%) is ranked lower than
55% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. RIGL: -67.70 )
RIGL' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 75.5
Current: -67.7

0
75.5
» RIGL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

RIGL Guru Trades in Q3 2013

Jim Simons 455,340 sh (+0.97%)
Chuck Royce 246,000 sh (unchged)
Steven Cohen 13,200 sh (-61.4%)
» More
Q4 2013

RIGL Guru Trades in Q4 2013

Jim Simons 1,150,139 sh (+152.59%)
Steven Cohen 21,600 sh (+63.64%)
Chuck Royce 308,992 sh (+25.61%)
» More
Q1 2014

RIGL Guru Trades in Q1 2014

Paul Tudor Jones 11,687 sh (New)
Charles Brandes 15,000 sh (New)
Steven Cohen 27,339 sh (+26.57%)
Chuck Royce 309,392 sh (+0.13%)
Jim Simons 210,526 sh (-81.7%)
» More
Q2 2014

RIGL Guru Trades in Q2 2014

Jim Simons 421,254 sh (+100.1%)
Paul Tudor Jones 11,950 sh (+2.25%)
Charles Brandes 15,000 sh (unchged)
Chuck Royce 215,392 sh (-30.38%)
» More
» Details

Insider Trades

Latest Guru Trades with RIGL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-03-31 New Buy$2.7 - $4.75 $ 2.6-26%15000
George Soros 2011-12-31 Sold Out 0.0019%$6.68 - $8.3 $ 2.6-66%0
George Soros 2011-06-30 New Buy$7.18 - $9.19 $ 2.6-68%14500
Jean-Marie Eveillard 2011-06-30 Sold Out $7.18 - $9.19 $ 2.6-68%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.38
RIGL's P/B is ranked higher than
88% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. RIGL: 1.38 )
RIGL' s 10-Year P/B Range
Min: 0.95   Max: 15.5
Current: 1.38

0.95
15.5
EV-to-EBIT -0.59
RIGL's EV-to-EBIT is ranked higher than
53% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. RIGL: -0.59 )
RIGL' s 10-Year EV-to-EBIT Range
Min: 6.1   Max: 10.5
Current: -0.59

6.1
10.5
Current Ratio 17.64
RIGL's Current Ratio is ranked higher than
98% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. RIGL: 17.64 )
RIGL' s 10-Year Current Ratio Range
Min: 1.84   Max: 36.3
Current: 17.64

1.84
36.3
Quick Ratio 17.64
RIGL's Quick Ratio is ranked higher than
98% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. RIGL: 17.64 )
RIGL' s 10-Year Quick Ratio Range
Min: 1.84   Max: 36.3
Current: 17.64

1.84
36.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.44
RIGL's Price/Net Cash is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. RIGL: 1.44 )
RIGL' s 10-Year Price/Net Cash Range
Min: 1.24   Max: 18.79
Current: 1.44

1.24
18.79
Price/Net Current Asset Value 1.44
RIGL's Price/Net Current Asset Value is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. RIGL: 1.44 )
RIGL' s 10-Year Price/Net Current Asset Value Range
Min: 1.22   Max: 17.79
Current: 1.44

1.22
17.79
Price/Tangible Book 1.38
RIGL's Price/Tangible Book is ranked higher than
91% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. RIGL: 1.38 )
RIGL' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 14.13
Current: 1.38

1.02
14.13
Earnings Yield (Greenblatt) 627.50
RIGL's Earnings Yield (Greenblatt) is ranked higher than
99% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. RIGL: 627.50 )
RIGL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 9.5   Max: 16.3
Current: 627.5

9.5
16.3
Forward Rate of Return (Yacktman) -39.23
RIGL's Forward Rate of Return (Yacktman) is ranked lower than
52% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. RIGL: -39.23 )
RIGL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -31.4   Max: -22.9
Current: -39.23

-31.4
-22.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:RI2A.Germany
Rigel Pharmaceuticals, Inc. was incorporated in Delaware in June 1996, and is based in South San Francisco, California. It is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis (RA) (partnered with AstraZeneca AB (AZ)), R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma, R548, an oral janus kinase 3 (JAK3) inhibitor in Phase 1 clinical trials for the treatment of transplant rejection and other immune disorders, and R333, a topical JAK/SYK inhibitor in Phase 1 clinical trials for the treatment of discoid lupus (lupus of the skin). The Company's major competitors include fully integrated pharmaceutical companies that have extensive drug discovery efforts and are developing novel small molecule pharmaceuticals. The Company is subject to extensive regulation by numerous governmental authorities in the United States and other countries, including the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for RIGL

Headlines

Articles On GuruFocus.com
Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

More From Our Partners
What You Need to Know About the Roche-InterMune Deal Aug 29 2014 - BENZINGA

More From Other Websites
RIGEL PHARMACEUTICALS INC Financials Aug 15 2014
Rigel's R348 Fails in Phase II Study, Shares Down 13.6% Aug 14 2014
Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today Aug 13 2014
Rigel eye drug fails mid-stage study, shares fall Aug 13 2014
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 13 2014
Rigel experimental eye drug fails mid-stage study Aug 13 2014
R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study Aug 13 2014
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 05 2014
RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2014
Rigel Announces Second Quarter 2014 Financial Results Aug 05 2014
Q2 2014 Rigel Pharmaceuticals Inc. Earnings Release - Before Market Open Aug 05 2014
Rigel Pharmaceuticals Starts Fostamatinib Late Stage Program Jul 17 2014
Rigel Initiates Phase 3 Studies of Fostamatinib in ITP Jul 16 2014
Rigel Pharmaceuticals initiates Phase 3 studies of fostamatinib in ITP Jul 16 2014
Rigel to Present at Jefferies 2014 Global Healthcare Conference May 29 2014
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission... May 27 2014
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2014
RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 07 2014
Rigel Announces First Quarter 2014 Financial Results May 07 2014
Rigel Announces Webcast of Investor Day on May 6, 2014 Apr 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK